Rosenblatt analyst Barton Crockett raised the firm’s price target on Stagwell (STGW) to $9 from $8 and keeps a Buy rating on the shares. Stagwell returned to peer-high organic growth in Q3, the analyst tells investors in a research note. The firm says the pressure Friday on sector peers, tied to concerns over pharma advertising, should not apply to Stagwell, which sold off its pharma business a year ago.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.